CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Global Learning Collaborative (GLC) designates this 15-minute enduring activity for a maximum of .25 AMA PRA Category 1 Credits™ and .25 nursing contact hours.
Dive into the intriguing realm of CAR T-cell therapy management, specifically pertaining to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Discover the latest clinical data and strategies to optimize patient outcomes.
Key Points:
- CAR T-cell therapy is a potentially transformative treatment for relapsed/refractory multiple myeloma.
- Current consensus grading systems exist for CRS and ICANS associated with CAR T-cell therapy.
- Understanding the signs and symptoms of CRS and ICANS is crucial for effective patient management.
Additional Points:
- Interdisciplinary team strategies are pivotal for successful management of CRS and ICANS in this patient population.
- This CME activity targets a wide array of healthcare professionals, including hematologists, oncologists, nurse practitioners, physician assistants, and nurses.
Conclusion:
- This educational activity serves as an essential guide for healthcare professionals seeking to deepen their understanding and effective management of CRS and ICANS in patients receiving CAR T-cell therapy.
Nursing Latest Posts
- First Lawsuit Filed Against Hospital Where Multiple Patients Reportedly Died After Receiving Tap Water Through IV Lines
- Inappropriate Prescribing to Older Patients by Nurse Practitioners and Primary Care Physicians
- Provision of Evaluation and Management Visits by Nurse Practitioners and Physician Assistants in the USA from 2013 to 2019: Cross-sectional Time Series study
- Chronotype, Unhealthy Lifestyle, and Diabetes Risk in Middle-Aged US Women
Did You Know?
According to research, CAR T-cell therapy has demonstrated impressive response rates of more than 80% in some studies with multiple myeloma patients who have exhausted other treatment options.
